Collectively, these findings identify GADD45β as an essential NF-κB-regulated survival factor and selective MKK7/JNK-axis inhibitor and, therefore, as a potential therapeutic target in MM. This evidence concerns the gene MAPK8 and Miyoshi myopathy.